Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients

Cheedy Jaja, Nadine Barrett, Niren Patel, Matthew L Lyon, Hongyan Xu, Abdullah Kutlar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: Interindividual variability in drug response and adverse effects have been described for proton pump inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, tricyclic antidepressants, and anti-infectives, but little is known about the safety and efficacy of these medications in patients with sickle cell disease (SCD). We genotyped the CYP2C19 gene which has been implicated in the metabolism of these drugs in an SCD patient cohort to determine the frequencies of reduced function, increased function, or complete loss-of-function variants. Materials and Methods: DNAs from 165 unrelated SCD patients were genotyped for nine CYP2C19 (∗2, ∗3, ∗4, ∗5, ∗6, ∗7,∗8, ∗12, and ∗17) alleles using the iPLEX® ADME PGx multiplex panel. Results: Three CYP2C19 alleles (∗2, ∗12, and ∗17) were detected with the following frequencies: 0.209, 0.006, and 0.236, respectively. The predicted phenotype frequencies were distributed as extensive (31.5%), intermediate (24.8%), poor (5.5%), ultrarapid (30.3%), and unknown metabolizers (7.9%). Discussion: Prognostic genotyping is potentially useful for identifying SCD patients with allelic variants linked to proven clinical pharmacokinetic consequences for several drugs metabolized by the CYP2C19 gene. However, the main challenge to implementing a genetics-guided prescribing practice is ensuring concordance between CYP2C19 genotypes and metabolic phenotypes in SCD patients.

Original languageEnglish (US)
Pages (from-to)609-615
Number of pages7
JournalGenetic Testing and Molecular Biomarkers
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Sickle Cell Anemia
Alleles
Pharmaceutical Preparations
Phenotype
Proton Pump Inhibitors
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Anticonvulsants
Genes
Pharmacokinetics
Genotype
Cytochrome P-450 CYP2C19
Safety
DNA

Keywords

  • drug metabolizing enzyme
  • pharmacogenetics
  • precision medicine
  • preemptive genotyping
  • sickle cell disease

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. / Jaja, Cheedy; Barrett, Nadine; Patel, Niren; Lyon, Matthew L; Xu, Hongyan; Kutlar, Abdullah.

In: Genetic Testing and Molecular Biomarkers, Vol. 20, No. 10, 01.10.2016, p. 609-615.

Research output: Contribution to journalArticle

@article{d261ca3f73c94b21962204764df20de0,
title = "Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients",
abstract = "Aims: Interindividual variability in drug response and adverse effects have been described for proton pump inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, tricyclic antidepressants, and anti-infectives, but little is known about the safety and efficacy of these medications in patients with sickle cell disease (SCD). We genotyped the CYP2C19 gene which has been implicated in the metabolism of these drugs in an SCD patient cohort to determine the frequencies of reduced function, increased function, or complete loss-of-function variants. Materials and Methods: DNAs from 165 unrelated SCD patients were genotyped for nine CYP2C19 (∗2, ∗3, ∗4, ∗5, ∗6, ∗7,∗8, ∗12, and ∗17) alleles using the iPLEX{\circledR} ADME PGx multiplex panel. Results: Three CYP2C19 alleles (∗2, ∗12, and ∗17) were detected with the following frequencies: 0.209, 0.006, and 0.236, respectively. The predicted phenotype frequencies were distributed as extensive (31.5{\%}), intermediate (24.8{\%}), poor (5.5{\%}), ultrarapid (30.3{\%}), and unknown metabolizers (7.9{\%}). Discussion: Prognostic genotyping is potentially useful for identifying SCD patients with allelic variants linked to proven clinical pharmacokinetic consequences for several drugs metabolized by the CYP2C19 gene. However, the main challenge to implementing a genetics-guided prescribing practice is ensuring concordance between CYP2C19 genotypes and metabolic phenotypes in SCD patients.",
keywords = "drug metabolizing enzyme, pharmacogenetics, precision medicine, preemptive genotyping, sickle cell disease",
author = "Cheedy Jaja and Nadine Barrett and Niren Patel and Lyon, {Matthew L} and Hongyan Xu and Abdullah Kutlar",
year = "2016",
month = "10",
day = "1",
doi = "10.1089/gtmb.2016.0001",
language = "English (US)",
volume = "20",
pages = "609--615",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients

AU - Jaja, Cheedy

AU - Barrett, Nadine

AU - Patel, Niren

AU - Lyon, Matthew L

AU - Xu, Hongyan

AU - Kutlar, Abdullah

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Aims: Interindividual variability in drug response and adverse effects have been described for proton pump inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, tricyclic antidepressants, and anti-infectives, but little is known about the safety and efficacy of these medications in patients with sickle cell disease (SCD). We genotyped the CYP2C19 gene which has been implicated in the metabolism of these drugs in an SCD patient cohort to determine the frequencies of reduced function, increased function, or complete loss-of-function variants. Materials and Methods: DNAs from 165 unrelated SCD patients were genotyped for nine CYP2C19 (∗2, ∗3, ∗4, ∗5, ∗6, ∗7,∗8, ∗12, and ∗17) alleles using the iPLEX® ADME PGx multiplex panel. Results: Three CYP2C19 alleles (∗2, ∗12, and ∗17) were detected with the following frequencies: 0.209, 0.006, and 0.236, respectively. The predicted phenotype frequencies were distributed as extensive (31.5%), intermediate (24.8%), poor (5.5%), ultrarapid (30.3%), and unknown metabolizers (7.9%). Discussion: Prognostic genotyping is potentially useful for identifying SCD patients with allelic variants linked to proven clinical pharmacokinetic consequences for several drugs metabolized by the CYP2C19 gene. However, the main challenge to implementing a genetics-guided prescribing practice is ensuring concordance between CYP2C19 genotypes and metabolic phenotypes in SCD patients.

AB - Aims: Interindividual variability in drug response and adverse effects have been described for proton pump inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, tricyclic antidepressants, and anti-infectives, but little is known about the safety and efficacy of these medications in patients with sickle cell disease (SCD). We genotyped the CYP2C19 gene which has been implicated in the metabolism of these drugs in an SCD patient cohort to determine the frequencies of reduced function, increased function, or complete loss-of-function variants. Materials and Methods: DNAs from 165 unrelated SCD patients were genotyped for nine CYP2C19 (∗2, ∗3, ∗4, ∗5, ∗6, ∗7,∗8, ∗12, and ∗17) alleles using the iPLEX® ADME PGx multiplex panel. Results: Three CYP2C19 alleles (∗2, ∗12, and ∗17) were detected with the following frequencies: 0.209, 0.006, and 0.236, respectively. The predicted phenotype frequencies were distributed as extensive (31.5%), intermediate (24.8%), poor (5.5%), ultrarapid (30.3%), and unknown metabolizers (7.9%). Discussion: Prognostic genotyping is potentially useful for identifying SCD patients with allelic variants linked to proven clinical pharmacokinetic consequences for several drugs metabolized by the CYP2C19 gene. However, the main challenge to implementing a genetics-guided prescribing practice is ensuring concordance between CYP2C19 genotypes and metabolic phenotypes in SCD patients.

KW - drug metabolizing enzyme

KW - pharmacogenetics

KW - precision medicine

KW - preemptive genotyping

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84992163145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992163145&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2016.0001

DO - 10.1089/gtmb.2016.0001

M3 - Article

C2 - 27551817

AN - SCOPUS:84992163145

VL - 20

SP - 609

EP - 615

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 10

ER -